Sino Biological Inc. Class A

Sino Biological Inc. Class A

SSZSE:301047
89.24
CNY
-2.68
(-2.92%)
1.47EPS
108.00P/E
19.34BMarket Cap
Apr 19Next Earn

Total Valuation

CNY

As of September 30, 2026, Sino Biological Inc. Class A carries a market capitalization of 19.34B, placing it among publicly traded companies globally. Its enterprise value stands at 16.42B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap19.34B
Enterprise Value16.42B

Important Dates

Sino Biological Inc. Class A's next confirmed earnings release is scheduled for April 19, 2027.

Earnings Date4/19/2027

Share Statistics

As of September 30, 2026, Sino Biological Inc. Class A has 121.64M shares outstanding.

Shares Outstanding121.64M

Valuation Ratios

As of September 30, 2026, Sino Biological Inc. Class A trades at a trailing price-to-earnings ratio of 108.00. The price-to-sales ratio is 24.42, and the price-to-book ratio stands at 3.74.

PE Ratio108.00
PS Ratio24.42
PB Ratio3.74
P/TBV Ratio3.97

Enterprise Valuation

As of September 30, 2026, Sino Biological Inc. Class A trades at an EV/EBITDA multiple of 76.31 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 20.73 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 76.31 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 16.42B versus a market cap of 19.34B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales20.73
EV / EBITDA76.31
EV / EBIT76.31

Financial Position

As of September 30, 2026, Sino Biological Inc. Class A maintains a current ratio of 21.73, meaning it holds 21.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.80, indicating moderate leverage, while an interest coverage ratio of 90.29 demonstrates strong ability to service its debt obligations.

Current Ratio21.73
Quick Ratio19.63
Debt / Equity0.80
Debt / EBITDA0.19
Interest Coverage90.29

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Sino Biological Inc. Class A posted a return on equity (ROE) of 3.29, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 3.25 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 3.16, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 3.29, useful for judging operating efficiency across full business cycles. The company generates approximately 740,872.20 in revenue per employee across its workforce of 1,069.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.71 indicates how many times Sino Biological Inc. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)3.29
Return on Assets (ROA)3.16
Return on Invested Capital (ROIC)3.25
Return on Capital Employed (ROCE)3.29
Revenue Per Employee740,872.20
Employee Count1,069.00
Inventory Turnover2.71

Taxes

CNY

Over the twelve months ended September 30, 2026, Sino Biological Inc. Class A recorded 35.91M in income tax expense. That works out to an effective tax rate of 16.71, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 214.98M, leaving 179.07M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax35.91M
Effective Tax Rate16.71

Stock Price Statistics

CNY

As of the close on November 17, 2026, Sino Biological Inc. Class A's stock has gained approximately 19.79% over the past 52 weeks. The 50-day moving average sits at 114.02, while the 200-day moving average is 85.11.

52-Week Price Change19.79%
50-Day Moving Average114.02
200-Day Moving Average85.11

Income Statement

CNY

Over the twelve months ended September 30, 2026, Sino Biological Inc. Class A generated 791.99M in revenue and converted that into 179.07M in net income, yielding earnings per share of 1.47. EBITDA reached 215.15M, while operating income came in at 156.52M.

Revenue791.99M
Gross Profit584.97M
Operating Income156.52M
Pretax Income214.98M
Net Income179.07M
EBITDA215.15M
EBIT215.15M
Earnings Per Share (EPS)1.47

Balance Sheet

CNY

As of September 30, 2026, Sino Biological Inc. Class A holds 2.96B in cash and equivalents against 41.14M in total debt, resulting in a net debt position of -202.27M. Total book value stands at 5.17B, with working capital of 3.13B providing operational flexibility.

Cash & Cash Equivalents2.96B
Total Debt41.14M
Net Debt-202.27M
Equity (Book Value)5.17B
Book Value Per Share42.47
Working Capital3.13B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-159.42M

Margins

Over the twelve months ended September 30, 2026, Sino Biological Inc. Class A posted a gross margin of 73.86, reflecting its pricing power and cost economics. The operating margin of 19.76 and net profit margin of 22.61 provide insight into operational efficiency.

Gross Margin73.86
Operating Margin19.76
Pretax Margin27.14
Profit Margin22.61
EBITDA Margin27.17

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Sino Biological Inc. Class A paid dividends of 1.00 per share. The dividend payout ratio of 67.93 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 1.53, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Sino Biological Inc. Class A shareholders.

Dividend Per Share1.00
Payout Ratio67.93
Shareholder Yield1.53

Stock Splits

Sino Biological Inc. Class A's most recent stock split took place on March 30, 2022 with a 10:19 split ratio.

Last Split Date3/30/2022
Split Ratio10:19

Scores

As of September 30, 2026, Sino Biological Inc. Class A has an Altman Z-Score of 51.67, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score51.67